Fig. 2: Silmitasertib decreases viability and proliferation of CRC cells. | Cell Death & Disease

Fig. 2: Silmitasertib decreases viability and proliferation of CRC cells.

From: CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells

Fig. 2

a Cell viability was determined by MTS assay in normal (CoN) and CRC cells (SW-480, DLD-1, HT-29, and HCT-116) after incubation with either vehicle (white bars) or 25 μM silmitasertib (black bars) for 48 h. b DLD-1 cells were treated as in a and proliferation was determined by CFSE staining and cytometry. c Protein levels of caspase-cleaved PARP-1 were detected by western blot in DLD-1 and HT-29 cells treated as in a. d DLD-1 cells treated with 25 μM silmitasertib for 24 and 48 h were analyzed through double positive annexin-V-FITC/PI staining by cytometry. Data represents the average ± SEM (n = 3); *p < 0.05

Back to article page